IP Library › Granted Patent US 11,224,581
Granted Patent B2
US 11,224,581 · App. 16/326,260 · Granted Jan 18, 2022

Composition for promoting ketone body production

Inventors: Kentaro Nakamura (Odawara, JP); Kinya Ashida (Odawara, JP); Akina Sasayama (Odawara, JP); Yuri Saito (Odawara, JP)
A61K31/198A23L33/12A23L33/175A61K31/185A61K31/20A61K31/225A61K31/23A61P3/02A61P3/04A61P3/10A61P9/04A61P9/10A61P25/00A61P25/06A61P25/08A61P25/16A61P25/24A61P25/28A61P35/00A61P43/00A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,224,581
App. No.
16/326,260
Granted
Jan 18, 2022
Kind
B2
Abstract

An object of the present invention is to provide a novel composition for promoting ketone body production. The present invention provides a composition for use in promoting ketone body production, comprising one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid. The composition according to the present invention may further comprise either or both of a medium-chain fatty acid and a medium-chain fatty acid ester.

Claims (7)

1. A method for promoting ketone body production to treat, prevent, or improve a disease or symptom that can be treated, prevented or improved by promoting ketone body production in a subject in need thereof, comprising feeding or administering to the subject one or more amino acid(s) selected from the group consisting of citrulline, leucine, cysteine, taurine, glutamine and aspartic acid in an amount effective to treat, prevent, or improve the disease or symptom.

2. The method of claim 1 , further comprising feeding or administering to the subject either or both of a medium-chain fatty acid and a medium-chain fatty acid ester in an amount effective to treat, prevent, or improve the disease or symptom.

3. The method of claim 1 , wherein the amino acid is provided in a food product.

4. The method of claim 2 , wherein the amino acid and either or both of the medium-chain fatty acid and medium-chain fatty acid ester are provided in a food product.

5. The method of claim 2 , wherein the amino acid and the a medium-chain fatty acid and/or a medium-chain fatty acid ester are administered in a molar ratio [(A)/(B)] of the amino acid(s) (A) to the medium-chain fatty acid and/or medium-chain fatty acid ester (B) ranges from 0.1 to 0.5.

6. The method of claim 5 , wherein the amino acid and either or both of the a medium-chain fatty acid and a medium-chain fatty acid ester are provided in a food product.

7. The method of claim 1 , wherein the disease and symptom are one or more selected from the group consisting of childhood epilepsy, intractable epilepsy, glucose transporter 1 (GLUT1) deficiency, pyruvate dehydrogenase complex disorder, Alzheimer's disease, neurodegenerative disease, mild cognitive impairment, Parkinson's disease, traumatic brain injury, cancer, depression, autism, migraine, amyotrophic lateral sclerosis, narcolepsy, diabetes, heart failure, myocardial infarction, angina pectoris, and obesity.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 18, 2019
From: NAKAMURA, KENTARO; ASHIDA, KINYA; SASAYAMA, AKINA; SAITO, YURI
To: MEIJI CO., LTD.
Reel/Frame 048359/0943 →
Priority Claims (1)
JP JP2016-161267 · Aug 19, 2016 · national
Continuity (1)
Related Publication 20190183828A1 · Jun 20, 2019
Cited By (1)
US 12,740,959